Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma
NCT05846724Phase 2Withdrawn
- Sponsor
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
- Start
- Feb 2024
- Primary completion
- Feb 2029
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and lenvatinib in Kaposi sarcoma (KS), sponsored by Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico. Primary endpoint: Overall Response Rate at 6 months. Planned start Feb 2024; status: withdrawn.
02
Drugs
pembrolizumablenvatinib
03
Conditions
Kaposi sarcoma (KS)
Beyond the preview
Go deeper on NCT05846724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05846724.